The primary aim of the study was to compare the efficacy of the IORT protocol against routine use of AWBI only, in 60-years-and-older breast cancer patients with ER-positive, without Her-2 overexpression tumors, with no clinically involved axillary lymph nodes. Here, ERBB2 is linked to breast cancer.